Latest Ratios: P/E Ratio 16.6x · EV/EBITDA 7.5x · ROE 16.1%. (1995–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $22.1B | $18.1B | $12.4B | $7.9B | $5.4B | $8.9B | $4.2B | $3.9B | $1.8B | $1.5B | $1.5B |
| Enterprise Value | $32.4B | $28.3B | $23.7B | $21.7B | $19.6B | $22.2B | $17.5B | $18.4B | $16.2B | $15.9B | $16.0B |
| P/E Ratio → | 16.56 | 12.83 | 3.86 | 13.23 | 12.87 | 9.70 | 10.65 | — | 16.02 | — | — |
| P/S Ratio | 1.04 | 0.85 | 0.60 | 0.39 | 0.28 | 0.46 | 0.24 | 0.21 | 0.10 | 0.08 | 0.08 |
| P/B Ratio | 2.60 | 2.01 | 1.45 | 1.44 | 1.17 | 2.08 | 1.47 | 1.98 | 0.85 | 0.63 | 0.42 |
| P/FCF | 8.73 | 7.13 | 11.07 | 4.88 | 16.80 | 9.75 | 1.48 | 6.98 | 4.12 | 3.09 | — |
| P/OCF | 6.24 | 5.10 | 6.04 | 3.34 | 4.98 | 5.66 | 1.25 | 3.19 | 1.70 | 1.27 | 2.64 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.33 | 1.15 | 1.06 | 1.02 | 1.14 | 0.99 | 1.00 | 0.88 | 0.83 | 0.82 |
| EV / EBITDA | 7.53 | 6.59 | 3.49 | 6.42 | 6.18 | 5.95 | 6.15 | 7.72 | 6.64 | 7.99 | 7.64 |
| EV / EBIT | 9.41 | 7.83 | 3.90 | 8.62 | 8.78 | 7.88 | 10.46 | 14.12 | 9.92 | 17.10 | 13.05 |
| EV / FCF | — | 11.20 | 21.20 | 13.37 | 61.10 | 24.34 | 6.11 | 32.72 | 37.49 | 32.15 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.3% | 82.3% | 39.7% | 38.0% | 36.8% | 37.3% | 35.3% | 36.3% | 36.4% | 35.4% | 36.4% |
| Operating Margin | 16.1% | 16.1% | 28.8% | 12.2% | 12.2% | 14.7% | 11.3% | 8.3% | 8.9% | 5.8% | 6.4% |
| Net Profit Margin | 6.6% | 6.6% | 15.5% | 3.0% | 2.1% | 4.7% | 2.3% | -1.2% | 0.6% | -3.7% | -1.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.1% | 16.1% | 45.5% | 12.1% | 9.3% | 25.6% | 16.4% | -10.5% | 4.6% | -23.9% | -5.7% |
| ROA | 4.8% | 4.8% | 11.2% | 2.2% | 1.5% | 3.3% | 1.6% | -0.9% | 0.5% | -2.9% | -0.8% |
| ROIC | 13.2% | 13.2% | 22.8% | 9.9% | 9.6% | 12.8% | 9.1% | 7.0% | 7.4% | 4.8% | 5.3% |
| ROCE | 13.8% | 13.8% | 24.7% | 10.9% | 10.3% | 12.8% | 9.6% | 8.2% | 8.7% | 5.6% | 6.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.47 | 1.47 | 1.68 | 2.72 | 3.27 | 3.68 | 5.44 | 7.42 | 7.04 | 6.21 | 4.39 |
| Debt / EBITDA | 3.06 | 3.06 | 2.11 | 4.44 | 4.75 | 4.20 | 5.52 | 6.18 | 6.08 | 7.53 | 7.27 |
| Net Debt / Equity | — | 1.15 | 1.32 | 2.50 | 3.09 | 3.12 | 4.59 | 7.28 | 6.84 | 5.96 | 4.18 |
| Net Debt / EBITDA | 2.39 | 2.39 | 1.67 | 4.08 | 4.48 | 3.56 | 4.66 | 6.07 | 5.91 | 7.22 | 6.93 |
| Debt / FCF | — | 4.07 | 10.13 | 8.49 | 44.30 | 14.60 | 4.63 | 25.74 | 33.37 | 29.06 | — |
| Interest Coverage | 4.41 | 4.41 | 7.35 | 2.79 | 2.51 | 3.05 | 1.67 | 1.32 | 1.63 | 0.90 | 1.25 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.76 | 1.76 | 1.78 | 1.51 | 1.34 | 1.38 | 1.47 | 1.21 | 1.20 | 1.29 | 1.30 |
| Quick Ratio | 1.68 | 1.68 | 1.70 | 1.42 | 1.25 | 1.31 | 1.40 | 1.13 | 1.12 | 1.22 | 1.22 |
| Cash Ratio | 0.65 | 0.65 | 0.70 | 0.26 | 0.19 | 0.46 | 0.50 | 0.06 | 0.11 | 0.14 | 0.18 |
| Asset Turnover | — | 0.72 | 0.71 | 0.73 | 0.71 | 0.71 | 0.65 | 0.79 | 0.82 | 0.82 | 0.79 |
| Inventory Turnover | 10.86 | 10.86 | 36.00 | 31.00 | 29.94 | 31.82 | 31.00 | 37.95 | 38.21 | 42.85 | 38.28 |
| Days Sales Outstanding | — | 43.93 | 53.94 | 60.47 | 65.90 | 61.93 | 69.34 | 64.47 | 61.65 | 57.57 | 63.84 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 6.0% | 7.8% | 25.9% | 7.6% | 7.8% | 10.3% | 9.4% | — | 6.2% | — | — |
| FCF Yield | 11.5% | 14.0% | 9.0% | 20.5% | 6.0% | 10.3% | 67.6% | 14.3% | 24.3% | 32.3% | — |
| Buyback Yield | 6.5% | 8.0% | 5.4% | 2.5% | 4.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 6.5% | 8.0% | 5.4% | 2.5% | 4.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $91M | $98M | $105M | $111M | $109M | $106M | $103M | $104M | $101M | $99M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying THC stock.
Tenet Healthcare Corporation's current P/E ratio is 16.6x. The historical average is 18.7x. This places it at the 61th percentile of its historical range.
Tenet Healthcare Corporation's current EV/EBITDA is 7.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 7.7x.
Tenet Healthcare Corporation's return on equity (ROE) is 16.1%. The historical average is -0.9%.
Based on historical data, Tenet Healthcare Corporation is trading at a P/E of 16.6x. This is at the 61th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Tenet Healthcare Corporation has 82.3% gross margin and 16.1% operating margin. Operating margin between 10-20% is typical for established companies.
Tenet Healthcare Corporation's Debt/EBITDA ratio is 3.1x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.
Key Metrics
Top Statement Risk
USPI concentration and revenue deferrals
Metrics are mathematically derived from official filings.
Margin Expansion Driven by Mix Shift
Operating margin improved to 18.2% in Q2 2026 from 15.6% a year earlier, per reported financials, reflecting the higher-margin ambulatory mix and disciplined cost control.
The sequential improvement in operating margin from 16.4% in Q1 2026 to 18.2% in Q2 2026 suggests that the shift toward USPI and higher-acuity services is translating into bottom-line leverage. However, the gross margin volatility—swinging from 82.3% in Q2 2025 to 18.2% in Q2 2026—indicates that the reported gross margin is not a reliable indicator of core profitability, as it likely excludes labor costs. Investors should focus on operating margin as the more stable measure of earning power, given the fixed-cost nature of hospital operations.
ROIC Recovery Signals Value Creation
ROIC improved to 4.0% in Q2 2026 from 3.2% in Q2 2024, per financial statements, suggesting that capital deployed into USPI is beginning to generate higher returns.
The upward trend in ROIC, albeit from a low base, indicates that management's portfolio reshaping toward ambulatory care is gradually improving capital efficiency. The spike in Q1 2024 (13.2%) was likely distorted by one-time gains, as subsequent quarters normalized to the 3-4% range. This suggests that the company is still in the early stages of compounding returns, and investors should monitor whether ROIC can sustain above 5% as the mix shift matures.
Working Capital Efficiency Improves
Cash conversion cycle turned negative to -39 days in Q2 2025, per reported data, reflecting favorable payment terms and efficient receivables management, though it has since normalized to 22 days.
The negative CCC in early 2025 was driven by a sharp increase in DPO to 131 days, which appears to be a timing anomaly rather than a sustainable trend, as DPO has since reverted to 27 days. DSO has improved from 62 days in Q2 2024 to 42 days in Q2 2026, indicating better collections, possibly due to a higher mix of managed care and government payers. Asset turnover remains low at 0.18, consistent with the capital-intensive hospital business, but the improvement in working capital metrics suggests operational discipline.
Leverage Elevated but Deleveraging Underway
Debt-to-EBITDA declined to 10.69 in Q2 2026 from 13.28 in Q2 2024, per reported figures, while interest coverage improved to 5.02, indicating gradually easing debt service burden.
Despite the high absolute leverage, the trend is favorable: D/E has fallen from 1.68 to 1.52 over the same period, and interest coverage has risen from 3.89 to 5.02. This suggests that EBITDA growth is outpacing debt growth, likely due to margin expansion and disciplined capital allocation. However, the D/EBITDA ratio remains elevated relative to peers like HCA (8.85), indicating that Tenet still carries a heavier debt load, which could constrain financial flexibility in a rising rate environment.
Liquidity Buffer Adequate but Thin
Current ratio improved to 1.41 in Q2 2026 from 1.44 in Q1 2024, per balance sheet data, with cash of $2.2B providing a modest cushion against short-term obligations.
The quick ratio of 1.35 indicates that inventory is not a significant liquidity concern, which is typical for a services business. However, the current ratio is only slightly above 1, suggesting that the company relies on ongoing cash flows to meet near-term liabilities. Under a severe stress scenario—such as a prolonged downturn in elective procedures—the liquidity position could become strained, especially given the high fixed-cost structure and debt service requirements.
Misapplied EV/EBITDA Multiple
EV/EBITDA of 8.01 appears cheap, but it understates Tenet's true leverage and the drag from non-controlling interests, per reported financials, warranting a sum-of-the-parts approach.
The EV/EBITDA multiple is commonly used to compare hospital operators, but for Tenet it is misleading because a significant portion of EBITDA is generated by USPI, where non-controlling physician partners own a stake. This means that consolidated EBITDA overstates the cash flow available to Tenet shareholders. Additionally, the high debt load inflates EV, making the multiple appear artificially low. Investors should instead use EV/EBITDAR or a sum-of-the-parts valuation that assigns a higher multiple to the USPI segment and a lower one to the hospital operations, as the market may be applying a conglomerate discount.